Risdiplam (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Risdiplam" in English language version.

refsWebsite

Global rank English rank

8web.archive.org

1^st place

7doi.org

2^nd place

7nih.gov

4^th place

5worldcat.org

5^th place

3smanewstoday.com

low place

3loc.gov

70^th place

63^rd place

3europa.eu

68^th place

117^th place

2tga.gov.au

3,984^th place

2,622^nd place

2semanticscholar.org

11^th place

8^th place

1hres.ca

low place

1canada.ca

1,712^th place

1,063^rd place

1fda.gov

447^th place

338^th place

1gene.com

low place

1neurology.org

9,919^th place

low place

1roche.com

low place

1prnewswire.com

406^th place

258^th place

1handle.net

102^nd place

76^th place

1smauk.org.uk

low place

canada.ca

"Health product highlights 2021: Annexes of products approved in 2021". Health Canada. 3 August 2022. Retrieved 25 March 2024.

doi.org

Zhao X, Feng Z, Ling KK, Mollin A, Sheedy J, Yeh S, et al. (May 2016). "Pharmacokinetics, pharmacodynamics, and efficacy of a small-molecule SMN2 splicing modifier in mouse models of spinal muscular atrophy". Human Molecular Genetics. 25 (10). Oxford, United Kingdom of Great Britain: Oxford University Press (OUP): 1885–1899. doi:10.1093/hmg/ddw062. PMC 5062580. PMID 26931466.
Ratni H, Ebeling M, Baird J, Bendels S, Bylund J, Chen KS, et al. (August 2018). "Discovery of Risdiplam, a Selective Survival of Motor Neuron-2 ( SMN2) Gene Splicing Modifier for the Treatment of Spinal Muscular Atrophy (SMA)". Journal of Medicinal Chemistry. 61 (15). Washington, D.C.: 6501–6517. doi:10.1021/acs.jmedchem.8b00741. LCCN a63000643. OCLC 39480771. PMID 30044619.
Ramdas S, Servais L (February 2020). Grech D, Mikhailidis D, Abdollahi M (eds.). "New treatments in spinal muscular atrophy: an overview of currently available data". Expert Opinion on Pharmacotherapy. 21 (3). London, England, United Kingdom of Great Britain: Taylor & Francis (Informa UK Ltd): 307–315. doi:10.1080/14656566.2019.1704732. OCLC 57378019. PMID 31973611. S2CID 210880199.
Baranello G, Darras BT, Day JW, Deconinck N, Klein A, Masson R, et al. (March 2021). "Risdiplam in Type 1 Spinal Muscular Atrophy". The New England Journal of Medicine. 384 (10). Boston, Massachusetts, United States of America: NEJM Group (Massachusetts Medical Society): 915–923. doi:10.1056/NEJMoa2009965. LCCN 20020456. OCLC 231027780. PMID 33626251. S2CID 232047598.
Zanetta C, Nizzardo M, Simone C, Monguzzi E, Bresolin N, Comi GP, Corti S (January 2014). "Molecular therapeutic strategies for spinal muscular atrophies: current and future clinical trials". Clinical Therapeutics. 36 (1). Philadelphia, Pennsylvania, United States of America: Elsevier: 128–140. doi:10.1016/j.clinthera.2013.11.006. PMID 24360800.
Baranello G, Servais L, Day J, Deconinck N, Mercuri E, Klein A, et al. (1 October 2019). "P.353FIREFISH Part 1: 16-month safety and exploratory outcomes of risdiplam (RG7916) treatment in infants with type 1 spinal muscular atrophy". Neuromuscular Disorders. 29 (Supplement 1). London, United Kingdom of Great Britain: World Muscle Society (WMS)/Elsevier Inc.: S184. doi:10.1016/j.nmd.2019.06.515. ISSN 0960-8966. OCLC 24318845.
Mercuri E, Baranello G, Kirschner J, Servais L, Goemans N, Pera MC, et al. (16 April 2019). "Update from SUNFISH Part 1: Safety, Tolerability and PK/PD from the Dose-Finding Study, Including Exploratory Efficacy Data in Patients with Type 2 or 3 Spinal Muscular Atrophy (SMA) Treated with Risdiplam (RG7916) (S25.007)". Neurology. 92 (15 (Supplement)). Minneapolis, Minnesota, United States of America: American Academy of Neurology/Wolters Kluwer. doi:10.1212/WNL.92.15_supplement.S25.007. ISSN 0028-3878. LCCN 55043902. OCLC 960771045. Retrieved 9 June 2021.

europa.eu

ema.europa.eu

"Evrysdi EPAR". European Medicines Agency. 24 February 2021. Retrieved 4 March 2023.
Stoyanova-Beninska V, Schwarzer-Daum B (26 February 2019). Public summary of opinion on orphan designation: Risdiplam for the treatment of spinal muscular atrophy (PDF). EMA Committee for Orphan Medicinal Products (COMP) (Report). Amsterdam, the Netherlands: European Medicines Agency (EMA Committee for Orphan Medicinal Products). pp. 1–4. Archived (PDF) from the original on 6 May 2020.

ec.europa.eu

"Evrysdi Product information". Union Register of medicinal products. Retrieved 3 March 2023.

fda.gov

O'Keefe L (7 August 2020). "FDA Approves Oral Treatment for Spinal Muscular Atrophy" (Press release). Silver Spring, Maryland, United States of America: United States Food and Drug Administration (FDA). FDA Newsroom Department. Archived from the original on 11 August 2020. Retrieved 7 August 2020. This article incorporates text from this source, which is in the public domain.

gene.com

"FDA Approves Genentech's Evrysdi (risdiplam) for Treatment of Spinal Muscular Atrophy (SMA) in Adults and Children 2 Months and Older". Genentech (Press release). San Francisco, California, United States of America: Genentech, Inc. (Roche Group). Genentech Global Product Development Division. 7 August 2020. Archived from the original on 18 August 2020. Retrieved 7 August 2020.

handle.net

hdl.handle.net

World Health Organization (2018). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 80". WHO Drug Information. 32 (3): 482. hdl:10665/330907.

hres.ca

hpr-rps.hres.ca

"Summary Basis of Decision (SBD) for Evrysdi". Health Canada. 23 October 2014. Retrieved 29 May 2022.

loc.gov

lccn.loc.gov

Ratni H, Ebeling M, Baird J, Bendels S, Bylund J, Chen KS, et al. (August 2018). "Discovery of Risdiplam, a Selective Survival of Motor Neuron-2 ( SMN2) Gene Splicing Modifier for the Treatment of Spinal Muscular Atrophy (SMA)". Journal of Medicinal Chemistry. 61 (15). Washington, D.C.: 6501–6517. doi:10.1021/acs.jmedchem.8b00741. LCCN a63000643. OCLC 39480771. PMID 30044619.
Baranello G, Darras BT, Day JW, Deconinck N, Klein A, Masson R, et al. (March 2021). "Risdiplam in Type 1 Spinal Muscular Atrophy". The New England Journal of Medicine. 384 (10). Boston, Massachusetts, United States of America: NEJM Group (Massachusetts Medical Society): 915–923. doi:10.1056/NEJMoa2009965. LCCN 20020456. OCLC 231027780. PMID 33626251. S2CID 232047598.
Mercuri E, Baranello G, Kirschner J, Servais L, Goemans N, Pera MC, et al. (16 April 2019). "Update from SUNFISH Part 1: Safety, Tolerability and PK/PD from the Dose-Finding Study, Including Exploratory Efficacy Data in Patients with Type 2 or 3 Spinal Muscular Atrophy (SMA) Treated with Risdiplam (RG7916) (S25.007)". Neurology. 92 (15 (Supplement)). Minneapolis, Minnesota, United States of America: American Academy of Neurology/Wolters Kluwer. doi:10.1212/WNL.92.15_supplement.S25.007. ISSN 0028-3878. LCCN 55043902. OCLC 960771045. Retrieved 9 June 2021.

neurology.org

n.neurology.org

Mercuri E, Baranello G, Kirschner J, Servais L, Goemans N, Pera MC, et al. (16 April 2019). "Update from SUNFISH Part 1: Safety, Tolerability and PK/PD from the Dose-Finding Study, Including Exploratory Efficacy Data in Patients with Type 2 or 3 Spinal Muscular Atrophy (SMA) Treated with Risdiplam (RG7916) (S25.007)". Neurology. 92 (15 (Supplement)). Minneapolis, Minnesota, United States of America: American Academy of Neurology/Wolters Kluwer. doi:10.1212/WNL.92.15_supplement.S25.007. ISSN 0028-3878. LCCN 55043902. OCLC 960771045. Retrieved 9 June 2021.

nih.gov

pubmed.ncbi.nlm.nih.gov

Zhao X, Feng Z, Ling KK, Mollin A, Sheedy J, Yeh S, et al. (May 2016). "Pharmacokinetics, pharmacodynamics, and efficacy of a small-molecule SMN2 splicing modifier in mouse models of spinal muscular atrophy". Human Molecular Genetics. 25 (10). Oxford, United Kingdom of Great Britain: Oxford University Press (OUP): 1885–1899. doi:10.1093/hmg/ddw062. PMC 5062580. PMID 26931466.
Ratni H, Ebeling M, Baird J, Bendels S, Bylund J, Chen KS, et al. (August 2018). "Discovery of Risdiplam, a Selective Survival of Motor Neuron-2 ( SMN2) Gene Splicing Modifier for the Treatment of Spinal Muscular Atrophy (SMA)". Journal of Medicinal Chemistry. 61 (15). Washington, D.C.: 6501–6517. doi:10.1021/acs.jmedchem.8b00741. LCCN a63000643. OCLC 39480771. PMID 30044619.
Ramdas S, Servais L (February 2020). Grech D, Mikhailidis D, Abdollahi M (eds.). "New treatments in spinal muscular atrophy: an overview of currently available data". Expert Opinion on Pharmacotherapy. 21 (3). London, England, United Kingdom of Great Britain: Taylor & Francis (Informa UK Ltd): 307–315. doi:10.1080/14656566.2019.1704732. OCLC 57378019. PMID 31973611. S2CID 210880199.
Baranello G, Darras BT, Day JW, Deconinck N, Klein A, Masson R, et al. (March 2021). "Risdiplam in Type 1 Spinal Muscular Atrophy". The New England Journal of Medicine. 384 (10). Boston, Massachusetts, United States of America: NEJM Group (Massachusetts Medical Society): 915–923. doi:10.1056/NEJMoa2009965. LCCN 20020456. OCLC 231027780. PMID 33626251. S2CID 232047598.
Zanetta C, Nizzardo M, Simone C, Monguzzi E, Bresolin N, Comi GP, Corti S (January 2014). "Molecular therapeutic strategies for spinal muscular atrophies: current and future clinical trials". Clinical Therapeutics. 36 (1). Philadelphia, Pennsylvania, United States of America: Elsevier: 128–140. doi:10.1016/j.clinthera.2013.11.006. PMID 24360800.

dailymed.nlm.nih.gov

Food and Drugs Administration (FDA) (18 August 2020). "Evrysdi- risdiplam powder, for solution". DailyMed. Bethesda, Maryland, United States: MedLine by the National Library of Medicine (NLM) of the United States National Institutes of Health (NIH). Retrieved 24 September 2020.

ncbi.nlm.nih.gov

Zhao X, Feng Z, Ling KK, Mollin A, Sheedy J, Yeh S, et al. (May 2016). "Pharmacokinetics, pharmacodynamics, and efficacy of a small-molecule SMN2 splicing modifier in mouse models of spinal muscular atrophy". Human Molecular Genetics. 25 (10). Oxford, United Kingdom of Great Britain: Oxford University Press (OUP): 1885–1899. doi:10.1093/hmg/ddw062. PMC 5062580. PMID 26931466.

prnewswire.com

PTC Therapeutics (17 August 2020). "PTC Announces the Acceptance of the European Marketing Authorization Application for Evrysdi™ (risdiplam) for the Treatment of Spinal Muscular Atrophy" (Press release). Albuquerque, New Mexico, United States of America: PR Newswire. PTC Therapeutics. Archived from the original on 18 August 2020. Retrieved 9 June 2021.

roche.com

Roche Group Media Relations Division (17 December 2018). "PRIME designation granted by European Medicines Agency for Roche's risdiplam for treatment of spinal muscular atrophy (SMA)" (Press release). Basel, Switzerland: F. Hoffmann-La Roche Ltd. Group Communications Department (Roche Group Media Relations Division). pp. 1–5. Archived from the original (PDF) on 18 August 2020. Retrieved 9 June 2021.

semanticscholar.org

api.semanticscholar.org

Ramdas S, Servais L (February 2020). Grech D, Mikhailidis D, Abdollahi M (eds.). "New treatments in spinal muscular atrophy: an overview of currently available data". Expert Opinion on Pharmacotherapy. 21 (3). London, England, United Kingdom of Great Britain: Taylor & Francis (Informa UK Ltd): 307–315. doi:10.1080/14656566.2019.1704732. OCLC 57378019. PMID 31973611. S2CID 210880199.
Baranello G, Darras BT, Day JW, Deconinck N, Klein A, Masson R, et al. (March 2021). "Risdiplam in Type 1 Spinal Muscular Atrophy". The New England Journal of Medicine. 384 (10). Boston, Massachusetts, United States of America: NEJM Group (Massachusetts Medical Society): 915–923. doi:10.1056/NEJMoa2009965. LCCN 20020456. OCLC 231027780. PMID 33626251. S2CID 232047598.

smanewstoday.com

Food and Drugs Administration (FDA) (7 August 2020). "Evrysdi (Risdiplam) for Spinal Muscular Atrophy". SMA News Today. Pensacola, Florida, United States: BioNews Services (BioNews Services, LLC.). Archived from the original on 27 January 2021. Retrieved 9 June 2021.
"RG7916". Pensacola, Florida, United States: BioNews Services (BioNews Services, LLC.). 8 November 2016. Archived from the original on 24 April 2020. Retrieved 9 June 2021.
Inacio P (21 December 2018). "Risdiplam Granted EMA's PRIME Designation for Potential in Spinal Muscular Atrophy". SMA News Today. Pensacola, Florida, United States: BioNews Services (BioNews Services, LLC.). Archived from the original on 26 January 2021. Retrieved 9 June 2021.

smauk.org.uk

Petridis F (13 January 2020). "Roche announces global compassionate use programme for Risdiplam" (Press release). Stratford-upon-Avon, England, United Kingdom of Great Britain: Spinal Muscular Atrophy UK ltd. Roche Global SMA Team (F. Hoffmann-La Roche Ltd). Retrieved 9 June 2021.

tga.gov.au

"Evrysdi". Therapeutic Goods Administration (TGA). 11 June 2021. Retrieved 6 September 2021.
"AusPAR: Risdiplam". Therapeutic Goods Administration (TGA). 13 September 2021. Retrieved 13 September 2021.

web.archive.org

O'Keefe L (7 August 2020). "FDA Approves Oral Treatment for Spinal Muscular Atrophy" (Press release). Silver Spring, Maryland, United States of America: United States Food and Drug Administration (FDA). FDA Newsroom Department. Archived from the original on 11 August 2020. Retrieved 7 August 2020. This article incorporates text from this source, which is in the public domain.
Food and Drugs Administration (FDA) (7 August 2020). "Evrysdi (Risdiplam) for Spinal Muscular Atrophy". SMA News Today. Pensacola, Florida, United States: BioNews Services (BioNews Services, LLC.). Archived from the original on 27 January 2021. Retrieved 9 June 2021.
"FDA Approves Genentech's Evrysdi (risdiplam) for Treatment of Spinal Muscular Atrophy (SMA) in Adults and Children 2 Months and Older". Genentech (Press release). San Francisco, California, United States of America: Genentech, Inc. (Roche Group). Genentech Global Product Development Division. 7 August 2020. Archived from the original on 18 August 2020. Retrieved 7 August 2020.
"RG7916". Pensacola, Florida, United States: BioNews Services (BioNews Services, LLC.). 8 November 2016. Archived from the original on 24 April 2020. Retrieved 9 June 2021.
Inacio P (21 December 2018). "Risdiplam Granted EMA's PRIME Designation for Potential in Spinal Muscular Atrophy". SMA News Today. Pensacola, Florida, United States: BioNews Services (BioNews Services, LLC.). Archived from the original on 26 January 2021. Retrieved 9 June 2021.
Roche Group Media Relations Division (17 December 2018). "PRIME designation granted by European Medicines Agency for Roche's risdiplam for treatment of spinal muscular atrophy (SMA)" (Press release). Basel, Switzerland: F. Hoffmann-La Roche Ltd. Group Communications Department (Roche Group Media Relations Division). pp. 1–5. Archived from the original (PDF) on 18 August 2020. Retrieved 9 June 2021.
Stoyanova-Beninska V, Schwarzer-Daum B (26 February 2019). Public summary of opinion on orphan designation: Risdiplam for the treatment of spinal muscular atrophy (PDF). EMA Committee for Orphan Medicinal Products (COMP) (Report). Amsterdam, the Netherlands: European Medicines Agency (EMA Committee for Orphan Medicinal Products). pp. 1–4. Archived (PDF) from the original on 6 May 2020.
PTC Therapeutics (17 August 2020). "PTC Announces the Acceptance of the European Marketing Authorization Application for Evrysdi™ (risdiplam) for the Treatment of Spinal Muscular Atrophy" (Press release). Albuquerque, New Mexico, United States of America: PR Newswire. PTC Therapeutics. Archived from the original on 18 August 2020. Retrieved 9 June 2021.

worldcat.org

search.worldcat.org

Ratni H, Ebeling M, Baird J, Bendels S, Bylund J, Chen KS, et al. (August 2018). "Discovery of Risdiplam, a Selective Survival of Motor Neuron-2 ( SMN2) Gene Splicing Modifier for the Treatment of Spinal Muscular Atrophy (SMA)". Journal of Medicinal Chemistry. 61 (15). Washington, D.C.: 6501–6517. doi:10.1021/acs.jmedchem.8b00741. LCCN a63000643. OCLC 39480771. PMID 30044619.
Ramdas S, Servais L (February 2020). Grech D, Mikhailidis D, Abdollahi M (eds.). "New treatments in spinal muscular atrophy: an overview of currently available data". Expert Opinion on Pharmacotherapy. 21 (3). London, England, United Kingdom of Great Britain: Taylor & Francis (Informa UK Ltd): 307–315. doi:10.1080/14656566.2019.1704732. OCLC 57378019. PMID 31973611. S2CID 210880199.
Baranello G, Darras BT, Day JW, Deconinck N, Klein A, Masson R, et al. (March 2021). "Risdiplam in Type 1 Spinal Muscular Atrophy". The New England Journal of Medicine. 384 (10). Boston, Massachusetts, United States of America: NEJM Group (Massachusetts Medical Society): 915–923. doi:10.1056/NEJMoa2009965. LCCN 20020456. OCLC 231027780. PMID 33626251. S2CID 232047598.
Baranello G, Servais L, Day J, Deconinck N, Mercuri E, Klein A, et al. (1 October 2019). "P.353FIREFISH Part 1: 16-month safety and exploratory outcomes of risdiplam (RG7916) treatment in infants with type 1 spinal muscular atrophy". Neuromuscular Disorders. 29 (Supplement 1). London, United Kingdom of Great Britain: World Muscle Society (WMS)/Elsevier Inc.: S184. doi:10.1016/j.nmd.2019.06.515. ISSN 0960-8966. OCLC 24318845.
Mercuri E, Baranello G, Kirschner J, Servais L, Goemans N, Pera MC, et al. (16 April 2019). "Update from SUNFISH Part 1: Safety, Tolerability and PK/PD from the Dose-Finding Study, Including Exploratory Efficacy Data in Patients with Type 2 or 3 Spinal Muscular Atrophy (SMA) Treated with Risdiplam (RG7916) (S25.007)". Neurology. 92 (15 (Supplement)). Minneapolis, Minnesota, United States of America: American Academy of Neurology/Wolters Kluwer. doi:10.1212/WNL.92.15_supplement.S25.007. ISSN 0028-3878. LCCN 55043902. OCLC 960771045. Retrieved 9 June 2021.